Oric Pharmaceuticals Inc (ORIC) ニュース

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

Form 8-K - Current report

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

Form 8-K - Current report

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in...

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc...

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]